Jean‐Marc Léger

Jean‐Marc Léger

From The Service D'explorations Fonctionnelles, Neurologie (Drs. Birouk, Maisonobe, Gouider, Gugenheim, Léger, And Bouche), The Inserm U289(Ms. Tardieu, Drs. Rouger And ...

Direct Impact

Concepts for which Jean‐Marc Léger has direct influence:

multifocal motor neuropathy
intravenous immunoglobulin
peripheral neuropathies
plasma exchange
neurological complications
immunosuppressive agents
skin biopsy

External impact

Concepts related to the work of other authors for which Jean‐Marc Léger has influence:

multifocal motor neuropathy
intravenous immunoglobulin
idera pharmaceuticals
grip strength
motor neuron
urinary incontinence
conduction block

Prominent publications by Jean‐Marc Léger

KOL-Index: 70 OBJECTIVES: Infliximab (IFX) appears to be effective in refractory sarcoidosis. However, data are lacking regarding its efficacy in severe sarcoidosis (i.e. with cardiac and/or neurological involvement). METHODS: Retrospective single-centre study including 16 unselected consecutive patients with biopsy proven, severe, and resistant sarcoidosis, who were treated by infliximab (3 or 5 mg /kg ...
Known for
Months Observed | Sarcoidosis Infectious | Cardiac Central Nervous Involvements | Thirty-Eight Percent
KOL-Index: 57 The Jamar dynamometer and Vigorimeter have been used to assess grip strength in immune-mediated neuropathies, but have never been compared to each other. Therefore, we performed a comparison study between these two devices in patients with immune-mediated neuropathies. Grip strength data were collected in 102 cross-sectional stable and 163 longitudinal (new diagnoses or changing condition) ...
Known for
Neuropathies | Responsiveness Aspects | Meaningful | Guillain-Barré Syndrome
KOL-Index: 54 PURPOSE OF THE STUDY: Somatosensory-evoked potentials with segmental recordings were performed with the aim of distinguishing chronic inflammatory demyelinating polyneuropathy from other sensory neuropathies. PATIENTS AND METHODS: Four groups of 20 subjects each corresponded to patients with (1) possible sensory chronic inflammatory demyelinating polyneuropathy, (2) patients with sensory ...
Known for
Time Neuropathies | Proximal Abnormality | Segmental Recordings | Polyneuropathy Abnormal
KOL-Index: 48 BACKGROUND: Multifocal motor neuropathy (MMN) is characterised by progressive, predominantly distal, asymmetrical limb weakness and usually multiple partial motor nerve conduction blocks. Intravenous immunoglobulin (IVIg) is beneficial but the role of immunosuppressive agents is uncertain. This is an update of a review first published in 2002 and previously updated in 2003, 2005, 2008 and ...
Known for
Authors Searched | Agents Multifocal | Prospective Retrospective | Strength Mmn
KOL-Index: 44 BACKGROUND: Multifocal motor neuropathy is characterised by progressive, predominantly distal, asymmetrical limb weakness and usually multiple partial motor nerve conduction blocks. Intravenous immunoglobulin is beneficial but the role of immunosuppressive agents is uncertain. OBJECTIVES: To provide the best available evidence from randomised controlled trials on the role of ...
Known for
Trial Immunosuppressive | Discussion Authors | Register October | Update Searched
KOL-Index: 37 Azacitidine (AZA) is a hypomethylating drug used to treat disorders associated with myelodysplasia and related neoplasms. Approximately 50 % of patients do not respond to AZA and have very poor outcomes. There is thus great interest in identifying predictive biomarkers for AZA responsiveness. We searched for specific genes whose expression level was associated with response status. Using ...
KOL-Index: 34 PURPOSE OF REVIEW: Multifocal motor neuropathy (MMN) has specific clinical and electrophysiologic features but can be difficult to diagnose if cases are not typical. Intravenous immunoglobulin (IVIg) remains the core initial and long-term treatment. In this review, recent advances in the diagnosis, monitoring and treatment of MMN are discussed. RECENT FINDINGS: The pathology of MMN likely ...
Known for
Pathophysiology Mmn | Neuropathy Multifocal
KOL-Index: 33 The objectives of this study were to provide an overview of the outcome measures (OMs) applied in clinical trials in multifocal motor neuropathy (MMN) and to determine the responsiveness of a core set of selected OMs as part of the peripheral neuropathy outcome measures standardization (PeriNomS) study. The following OMs were serially applied in 26 patients with newly diagnosed or relapsing ...
Known for
Neuropathy Impairment Motor-Subset | × Sd | Mcid-Se ≥ | Self-Evaluation
KOL-Index: 33 In patients with infectious cryoglobulinemia vasculitis (CryoVas) in the absence of hepatitis C virus infection, data on presentation, therapeutic management and outcome are lacking. We conducted a nationwide survey that included patients with HCV-negative CryoVas. We describe here the presentation, therapeutic management and outcome of 18 patients with non-HCV infectious CryoVas and 27 ...
Known for
Hcv-Negative Cryovas | Pyogenic Bacterial Infection | Infectious Agents | First-Line Therapy
KOL-Index: 32 BACKGROUND: Fingolimod is approved for the treatment of relapsing-remitting multiple sclerosis and was effective in experimental autoimmune neuritis in rats, a possible model for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). We aimed to evaluate the efficacy of fingolimod in delaying disability progression in patients with CIDP who withdrew from currently effective ...
Known for
Fingolimod Receiving | Confirmed Worsening | 13 | Ivig Corticosteroids

From the Service d'Explorations Fonctionnelles, Neurologie (Drs. Birouk, Maisonobe, Gouider, Gugenheim, Léger, and Bouche), the INSERM U289(Ms. Tardieu, Drs. Rouger and LeGuern and Drs. Brice and Agid), the Fédération de Neurologie (Drs. Brice and Ag

https://www.g2.com/products/key-opinion-leaders-kols/reviews https://www.bbb.org/us/fl/doral/profile/data-analytics/key-opinion-leaders-0633-92023858 https://www.trustpilot.com/review/keyopinionleaders.com https://www.yelp.com/biz/key-opinion-leaders-miami


© 2022 - Key Opinion Leaders -
Key Opinion Leaders, LLC ,
2025 NW 102 Avenue, Suite 111 Doral , FL   33172